Further, both in vitro and pre-clinical in vivo studies revealed the prominent role of anti-NGF therapies in promoting tumor regression and PNI inhibition, thereby suggesting that NGF may become a relevant target for future anticancer therapies. Here, NGF is linked to neoplasm.